Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | The evolutionary history of post-melphalan myeloid neoplasms

Francesco Maura • 22 Aug 2022
IMS 2022
Multiple Myeloma Melphalan

Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the results of a study using whole-genome sequencing (WGS) to characterize the mechanisms of risk to developing therapy-related myeloid neoplasms in patients with multiple myeloma treated with autologous hematopoietic stem cell transplantation (autoHSCT). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francesco Maura

SMM & MGUS: clinical relevance, the PROMISE study & the role of genomics
Elizabeth O'Donnell et al. • 25 Mar 2024
3:43
Genomic profiling to predict prognosis for patients with HR-SMM
Francesco Maura • 8 Dec 2023
1:15
Using genomic alterations to predict relapse following immunotherapy in multiple myeloma
Francesco Maura • 8 Dec 2023
2:08
Novel genomic alterations driving tumor suppressor gene inactivation in multiple myeloma
Francesco Maura • 8 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals